Floor (percentage of participants at minimum possible value) and ceiling (percentage of participants at maximum possible value) effects.
| Measure | Source | Floor (%) | Ceiling (%) | ||
|---|---|---|---|---|---|
| Baseline | Final* | Baseline | Final* | ||
| Pain (Likert) | MSD, Pfizer, Regeneron, Novartis | 0 | 42 | 21.7 | 1.8 |
| 0 | 35.4 | 17.7 | 0.8 | ||
| 0 | 11.6 | 11.1 | 4.0 | ||
| 0.24 | 28.25 | 12.59 | 1.25 | ||
| Pain (VAS) | AUT†, Novartis | 0 | 33.3 | 5 | 0 |
| 0 | 14.4 | 2.1 | 0 | ||
| Pain (NRS) | Regeneron | 0 | 11.6 | 9.3 | 4.9 |
| Joint tenderness | MSD, Pfizer, Regeneron, Novartis, AUT† | 0 | 50.0 | 57.5 | 3.0 |
| 0.5 | 44.1 | 39.1 | 4.7 | ||
| NA | NA | NA | NA | ||
| 0.71 | 55.1 | 43.4 | 2.64 | ||
| NA | NA | NA | NA | ||
| Joint swelling | MSD, Pfizer, Regeneron, Novartis, AUT† | 0 | 52.1 | 56.0 | 5.4 |
| 2.2 | 47.2 | 27.1 | 4.5 | ||
| NA | NA | NA | NA | ||
| 1.4 | 63.7 | 35.1 | 2.2 | ||
| NA | NA | NA | NA | ||
| Disability‡ | MSD, Pfizer, Regeneron, Novartis, AUT† | NA | NA | NA | NA |
| NA | NA | NA | NA | ||
| 11.7 | 33.2 | 8.1 | 3.5 | ||
| 5.63 | 46.19 | 0.43 | 0 | ||
| 0 | 0 | 0 | 16.7 | ||
| Patient Global Assessment¶ | MSD, Pfizer, Regeneron, Novartis, AUT† | NA | 4.5 | NA | 26.4 |
| NA | 2.8 | NA | 40.1 | ||
| NA | NA | NA | NA | ||
| NA | 2.1 | NA | 39.1 | ||
| 0 | 0 | 5 | 0 | ||
↵* Refers to Day 5 unless mentioned specifically;
↵† Final value at 6 to 8 wks;
↵‡ Measured by Health Assessment Questionnaire version II in AUT, Health Assessment Questionnaire Disability Index in Novartis, Worker Productivity and Activity Impairment Index 0–10 in Regeneron;
↵¶ Final value at Day 9 for Pfizer and Novartis. NA: measure not available; VAS: visual analog scale; NRS: numeric rating scale; AUT: Auckland University of Technology; HAQ-II: Health Assessment Questionnaire version II; HAQ-DI: Health Assessment Questionnaire Disability Index; WPAI:SHP: Worker Productivity and Activity Impairment Index (Specific Health Problem)9; MSD: Merck Sharp & Dohme Corp.